Thrombotic Microangiopathies

Similar documents
A 60 year old woman with altered mental status and thrombotic microangiopathy. Josh Veatch

DRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial)

Results of the TITAN study for Caplacizumab

Sara K. Vesely, James N. George, Bernhard Lämmle, Jan-Dirk Studt, Lorenzo Alberio, Mayez A. El-Harake, and Gary E. Raskob

DR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL

Presentation Outline. Disease Background Previous research on platelet recovery rate Goal of our study Methods Results Limitations Conclusions

Hemolytic uremic syndrome: Investigations and management

Things to never miss in the office. Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC

4100: Cellular Therapy Essential Data Follow-Up Form

INVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests

Thrombotic Thrombocytopenic

What is meant by Thrombotic Microangiopathy (TMA)?

Anemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017

Let`s go for the diagnosis! Yazeed Toukan, MD Pediatric Pulmonary Institute, Ruth Rappaport Children`s Hospital July 2016

* Renal insufficiencies

THROMBOTIC MICROANGIOPATHY. Jun-Ki Park 7/19/11

Most Common Hemostasis Consults: Thrombocytopenia

Thrombotic thrombocytopenic purpura: a look at the future

General History. 林陳 珠 Female 69 years old 住院期間 : ~ Chief Complaint : sudden loss of conscious 5 minutes in the morning.

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI CLINICAL RESEARCH CENTER ALDO E FOR CELE RARE DACCO DISEASES ALDO E CELE DACCO

A 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis).

BR for previously untreated or relapsed CLL

For platelet control as individual as you

Keeping track of your numbers

Mantle-Cell Leukemia: Lessons in Life and Death

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature

Thrombocytopenia: a practial approach

Haematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital

NEW HEMATOLOGY PARAMETERS

Long-Term Outcomes After Successful Treatment of TTP

By Your Sis: Ghada Odeh :)

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura

Putting the Pieces Together. Anne Longtine MD Internal Medicine Residency, Maine Medical Center Maine ACP Annual Meeting Clinical Vignette 9/16/2017

TENNCARE Bundled Payment Initiative: Description of Bundle Risk Adjustment for Wave 8 Episodes

Cytokine Release Syndrome and Neurotoxicity

Subject ID: I N D # # U A * Consent Date: Day Month Year

Anemia (3).ms4.25.Oct.15 Hemolytic Anemia. Abdallah Abbadi

Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13

An Uncommon Presentation of Large B-cell Lymphoma of the kidney A Case Report and Literature Review

Looking Outside the Box: Incidental Extracardiac Finding in Echo

3/9/2017. Chapter 56. Care of the Patient with Cancer. Cancer Rates in the US. Carcinogenesis

Case Scenario 1. Discharge Summary

Read the following article and answer the questions that follow. Refer to the Keys section to check your answers.

DOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.

Case Study #2. Case Study #1 cont 9/28/2011. CAPA 2011 Christy Wilson PA C. LH is 78 yowf with PMHx of metz breast CA presents

Abdominal Pain. Luke Donnelly, MD Emergency Medicine

Breast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer

Boot Camp Transfusion Reactions

Part 1 examination. Haematology: First paper. Tuesday 20 March Candidates must answer all questions. Each question is worth a total of 25 marks.

Discussion. Case conference. Anemia. The basic evaluation of a patient newly diagnosed with anemia. Speaker : R2 趙劭倫 Supervisor : VS 林立偉

BRAJACTT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician

Transfusion Reactions

Clinical Study Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

BC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel

Abstracting Hematopoietic Neoplasms

Pregnancy in the middle of adjuvant treatment of Her2 positive breast cancer

Approccio morfologico alle microangiopatie trombotiche

A Guide for Patients and Caregivers

Example Clinician Educational Material for Providers of Immune Effector Cellular Therapy

Supplementary Online Content

BC Cancer Protocol Summary for Therapy for Locally Recurrent or Metastatic, RAI-refractory Differentiated Thyroid Cancer Using Lenvatinib

BBTS Advanced Clinical and laboratory case studies. Therese Callaghan

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Summary of the risk management plan (RMP) for Kyprolis (carfilzomib)

This was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.

R-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative

Clinical & Laboratory Assessment

Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO. Avelumab 200 mg/10 ml. Concentrate for Solution for Infusion

ULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician

Cardiology III 1/22/2019. Disclosures - none. But first. Objectives. Ischemia EKG s. And second

BC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine

Fuel your determination to live longer with KYPROLIS. Look inside to learn more.

Choose the most appropriate action 10/8/2013 CASE REPORT. Case Report WHAT WOULD YOU DO NEXT? A. Discontinue heparin and start argatroban infusion

Supplementary Appendix

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities

Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R

Tumor Board Discussions: Case 1

Blood Transfusion Reactions

Chapter 1. Perioperative Evaluation and Management of Surgical Patients. Oral Exam Questions

ACUTE KIDNEY INJURY A PRIMER FOR PRIMARY CARE PHYSICIANS. Myriam Farah, MD, FRCPC

Anemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh

Transfusion Reactions. Directed by M-azad March 2012

For the Patient: USMAVFIPI

New insights in thrombotic microangiopathies : TTP and ahus

Patient Interview Form

Cycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline

Scottish Surveillance of Healthcare Associated Infection Programme (SSHAIP) Health Protection Scotland (HPS) SSI Surveillance Protocol 7th Edition

BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy

Chemotherapy for domestic animals

Part 1 examination. Haematology: First paper. Tuesday 25 September 2018

Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma

Blood is serious business

Infected cardiac-implantable electronic devices: diagnosis, and treatment

LAB 4: THE MUSCLE AND CARDIOVASCULAR SYSTEM THE MUSCLE AND CARDIOVASCULAR SYSTEM

ACCME/Disclosures 4/13/2016 IDPB

Acute Lymphocytic Leukemia Early Detection, Diagnosis, and Types

Oncologic Emergencies

Be Prepared Evacuation or not?

Transcription:

Thrombotic Microangiopathies ASH/San Antonio Breast Cancer Symposium Review James N. George March 14, 2015

Thrombotic Microangiopathies (TMA): Everything you need to know from 5 patient stories Thrombotic thrombocytopenic purpura (TTP) Role of ADAMTS13 measurements Role of rituximab Risk of pregnancy Role of bone marrow biopsy Drug-induced TMA Don t miss the diagnosis!

Zheng, and Sadler, Clinical Hematology (Young, et al., Eds) Mosby, 2006

Patient 1 (2001) 20 yo previously healthy BF, BMI 41 Uncomplicated first pregnancy, C-section 4 days pp: Hct 29, Plt 329 8 days pp: routine post-op. SOB, weak, dark urine, no neurologic signs. Hct 18, Plt 9, Cr 0.8, LDH 2316, red cell fragments PEX + steroids: 6 days Plt 199; stop PEX 56; resume 167; stop 97; resume 268 (26 PEX, 33 days) ADAMTS13 <10% (+ inhibitor)

Patient 1 2003, 2005: uncomplicated pregnancies 2004: remission ADAMTS13 100% 2006-2014: 8 remission ADAMTS13 measurements, all <10% (+ inhibitor); no symptoms, normal CBC 2015: She has remained normal since recovery from her initial TTP episode

Patient 1: Lessons Typical demographic features, typical presentation, typical clinical course Rituximab can (almost always) prevent prolonged requirement for PEX Subsequent pregnancies usually without complications, and without relapse Clinical importance of severe ADAMTS13 deficiency during remission is unknown

Patient 2 (1998) 41 yo previously healthy BM 3 days of abdominal pain, nausea, vomiting, diarrhea, weakness. Transient aphasia and numbness of his left face and arm. Hct 19, Plt 7, Cr 1.2, LDH 1946, red cell fragments Recovered with 6 PEX, no corticosteroids HIV positive

Episode Patient 2 ADAMTS13 Activity ADAMTS13 Inhibitor IB FRETS Flow IB FRETS 1 (1998) 60% 53% NL - - 2 (2000) - - - - - 3 (2000) 50% 15% - 1.4 4 (2001) 6% <5% Tr 0.8 5 (2003) <5% <5% 1 1.1 6 (2008) <5% <5% - 1-2 1.4 Haematologica 2012; 97: 297

Patient 2: Lessons Normal ADAMTS13 activity does not exclude the diagnosis of TTP Diagnosis of TTP and initiation of PEX are clinical decisions (This is not oncology, where diagnosis and treatment require pathology)

Patient 3 (2008) 55 yo previously healthy WF 3 days of chest pain, dyspnea, then right-side weakness, aphasia Hct 33, Plt 33, Cr 1.6, LDH 1084, red cell fragments, neg DAT, normal coagulation tests EKG, chemistries: MI; MRI: left MCA infarct, multiple cerebellar infarcts; TEE: aortic valve vegetation and regurgitation Blood cultures: Enterococcus

Patient 3 Diagnoses: Bacterial endocarditis (+ TTP) Treatment: Antibiotics, PEX, steroids Recovery to normal Plt, Cr, and LDH 3 months later: aortic valve replacement

Assay Patient 3 ADAMTS13 Activity ADAMTS13 Inhibitor IB FRETS IB FRETS Before PEX <5% <5% 0 0 2009 100% 92% - - 2010 50% <5% - 0

Patient 3: Lesson Severe ADAMTS13 deficiency supports (but does not confirm) the diagnosis of TTP or exclude alternative diagnoses

Patient 4 (2000) 52 yo woman, sudden abdominal pain and syncope, suspected cholecystitis 3 years previously: breast cancer, + axillary nodes, chemotherapy Hct 25, Plt 17, Cr 1.0, bilirubin 5.5 (direct, 1.6), LDH 1431, red cell fragments, INR/PTT 1.2/23, Fibrinogen 424, DAT neg. Chest x-ray, abdomen ultrasound, chest/abdomen CT: normal

Patient 4 PEX: no response over 3 days Day 3: Severe tachypnea, hypoxemia, bilateral pulmonary emboli Day 4: died Autopsy: No cause of death apparent No pulmonary thromboembolism Diagnosis: TTP

Patient 4 Autopsy microscopic report: Hyaline thrombi in brain, lungs, kidney Microscopic metastatic carcinoma in brain, lungs, kidneys, heart, liver, esophagus, adrenals, thyroid, spleen, marrow

Brain: Hyaline Thrombus

Brain: Metastatic Carcinoma

Lung: Hyaline Thrombus

Lung: Metastatic Carcinoma

Patient 4: Lessons Systemic malignancies can mimic all clinical features of TTP Consider a bone marrow biopsy in puzzling patients with atypical features (e.g., pulmonary symptoms, bone pain) especially patients with a history of malignancy

Patient 5 (2009) 35 yo previously healthy WF Sudden onset of nausea, vomiting, diarrhea, chills, fever, abdominal and back pain ER (Day 2): Hct 39, Plt 132, no chemistries, IV hydration, antiemetics ER (Day 4): Symptoms, except back pain, improved but continued anuria Hct 30, Plt 42, Cr 10.7, LDH 2402, AST/ALT 350/274, red cell fragments

Additional history Patient 5 Vodka and tonic at an employee recognition party about 1-2 hours preceding symptoms ( I only had a little sip.. ) Previous tonic water exposure 15 months before: sudden onset of severe headache, nausea, vomiting, chills, fever ER:? Meningitis; LP, CT head normal. Hct 35%, Plt 257, Cr 1.7 (subsequently 0.7)

Patient 5 Stop PEX after 13 days: Plt 150, Hct 27, Cr 7.9, LDH 370 Quinine-dependent antibodies reactive with platelets and neutrophils ADAMTS13 100% Hemodialysis continued for 2 months 2014: Cr 1.25, egfr 54, hypertension

Flow Cytometry Detection of Drug-Dependent Antibodies

Patient 5: Lesson Do NOT miss the diagnosis of quinine-induced TMA!